Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02911792 · ClinicalTrials.gov registry record · Phase 4
Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration
A Phase 4 study, sponsored by The University of Texas Health Science Center at San Antonio.
- Completed
- Registry status
- Phase 4
- Development phase
- 72
- Enrollment target
NCT02911792 is a Phase 4 study that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 72 participants.
The verdict
NCT02911792, a Phase 4 study, has completed, sponsored by The University of Texas Health Science Center at San Antonio.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 72 participants
- Enrollment target
Study Summary
The investigators propose to treat newly diagnosed, hyperfiltering T2DM patients with or without microalbuminuria with dapagliflozin or metformin for 4 months. The metformin-treated group will serve as controls for improved glycemic control, since the investigators have shown that insulin therapy to normalize A1c reduces hyperfiltration and kidney size in T1DM patients.
Interventions
- DRUG Metformin
- DRUG Dapagliflozin
- DRUG Glipizide 5 MG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2016-12-20 |
| Est. Completion | 2023-07-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02911792
The ClinicalTrials.gov registry entry for NCT02911792 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Metformin is the first listed.
NCT02911792 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02911792 about?
NCT02911792 is a clinical study titled "Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration". The investigators propose to treat newly diagnosed, hyperfiltering T2DM patients with or without microalbuminuria with dapagliflozin or metformin for 4 months. The metformin-treated group will serve as controls for improved glycemic control, since the investigators have shown that insulin therapy to...
What is the current status of trial NCT02911792?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 72 participants. The study started on 2016-12-20. Estimated completion is 2023-07-11.
What interventions are being tested in trial NCT02911792?
The interventions under investigation include: Metformin (DRUG), Dapagliflozin (DRUG), Glipizide 5 MG (DRUG).
Who is sponsoring clinical trial NCT02911792?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.